Close
  • 00 atmail

Kaiser Permanente expands use of ImpediMed's L-Dex Medical Device

Kaiser Permanente expands use of ImpediMed's L-Dex Medical Device

9 October 2013

ASX ANNOUNCEMENT

ONE OF THE LARGEST U.S. HEALTHCARE PROVIDERS EXPANDS USE OF L-DEX

Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“the Company”), the world leader of bioimpedance devices for aiding in the clinical assessment of unilateral lymphoedema, announces the expansion of Kaiser Permanente’s use of the L-Dex® U400 to their Southern California Region. The L-Dex U400s will be used initially at two outpatient facilities servicing a regional Kaiser Permanente hospital.

Kaiser Permanente is the largest not-for-profit health maintenance organisation in the United States. This expansion follows the initial adoption of the L-Dex technology by their Northern California Region. Three northern California facilities, two hospitals and their Breast Cancer Survivorship Institute have been using the L-Dex U400 since 2012.

President and CEO Richard Carreon stated, “I am very pleased to see the expanded use of our technology by such an innovative institution renowned for their focus on patient outcomes. We continue to see expansion of L-Dex technology at leading managed care organisations in the US.”

For further information contact:

Richard Carreon, ImpediMed CEO

Morten Vigeland, ImpediMed CFO

T: +1 (760) 585-2100

L-Dex® is a trademark of ImpediMed Limited.

About ImpediMed

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men. For more information, visit www.impedimed.com.au